
WO 2015/089361; WO 2017/209322; US 8,519,137; US 9,051,270; US 9,108,903; US 9,163,042; US 9,783,501; WO 2020/092667; WO2019/014352; WO2018/213426; US 8,629,149; and WO2011/026240.

SUMMARY


The present disclosure relates to novel compounds of structural formula I:



I

and pharmaceutically acceptable salts thereof.

In one aspect, the present disclosure relates to a compound of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

A is selected from the group consisting of:

1) phenyl, and
2) pyridine,

wherein each phenyl and pyridine is unsubstituted or substituted with one to five substituents selected from R^a,

B is independently selected from the group consisting of:

1) phenyl,
2) pyridine,
3) thiazole,
4) pyrimidine,
5) pyrazine,
6) pyridazine,
7) imidazole,
8) pyrazole,
9) oxazole,
10) benzofuran,
11) benzo[d]oxazole,
12) benzo[d]thiazole,
13) indazole,
14) thiazolo[5,4-b]pyridine,
15) pyrazolo[1,5-a]pyridine,
16) $-(CH_2)_2$-phenyl,
17) $-CH_2$-O-phenyl,
18) $-CH_2$-O-pyridine,
19) cyclobutane,
20) cyclohexane,
21) bicyclo[1.1.1]pentane,
22) spiro[3.3]heptane,
23) azetidine,
24) piperidine,
25) tetrahydropyran,
26) tetrahydrofuran,
27) azabicyclo[3.1.0]hexane,
28) $-CH_2$-cyclohexane,
29) $-CH_2$-tetrahydropyran,

30) -CH_2-O-cyclohexane, and

31) bicyclo[4.2.0]octatriene,

wherein B is unsubstituted or substituted with one to five substituents selected from R^b;

R^1 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^4 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^5 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

R^6 is hydrogen;

R^7 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

each R^a is independently selected from the group consisting of:

1) -CF_3,
2) -OCF_3,
3) -CHF_2,
4) -$OCHF_2$,
5) –CH_2CF_3,
6) –OCH_2CF_3,
7) –CF_2CH_3,
8) CN,
9) oxo,
10) halogen,
11) –$S(O)_2C_{1-6}$alkyl,
12) -C_{1-6}alkyl,
13) -C_{2-6}alkenyl,
14) -C_{2-6}alkynyl,
15) -C_{3-6}cycloalkyl,
16) -C_{2-6}cycloheteroalkyl,
17) aryl,
18) heteroaryl,
19) –C_{1-6}alkyl-aryl,
20) –C_{1-6}alkyl-heteroaryl,
21) –C_{1-6}alkyl-C_{3-6}cycloalkyl,
22) –C_{1-6}alkyl-C_{2-6}cycloheteroalkyl,
23) -C_{2-6}alkenyl-C_{3-6}cycloalkyl,
24) -C_{2-6}alkenyl-C_{2-6}cycloheteroalkyl,
25) –C_{2-6}alkenyl-aryl,
26) -C_{2-6}alkenyl-heteroaryl,
27) -C_{2-6}alkynyl-C_{3-6}cycloalkyl,
28) -C_{2-6}alkynyl-C_{2-6}cycloheteroalkyl,

29) -C_{2-6}alkynyl-aryl,

30) -C_{2-6}alkynyl-heteroaryl,

31) -OH,

32) -$(CH_2)_p$-O-C_{1-6}alkyl,

33) -$(CH_2)_p$ -O-C_{2-6}alkenyl,

34) -$(CH_2)_p$ -O-C_{2-6}alkynyl,

35) –$(CH_2)_p$ -O-C_{3-6}cycloalkyl,

36) –$(CH_2)_p$ -O-C_{2-6}heterocycloalkyl,

37) –$(CH_2)_p$ -O-aryl,

38) –$(CH_2)_p$ -O-heteroaryl,

39) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

40) -OC_{1-6}alkyl-C_{2-6}heterocycloalkyl,

41) -OC_{1-6}alkyl-aryl,

42) -OC_{1-6}alkyl-heteroaryl,

43) -$S(O)_mR^i$,

44) -C_{1-6}alkyl-$S(O)_mR^i$,

45) -$N(R^k)_2$, and

46) –NR^kR^L,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) -CHF_2,

4) -$OCHF_2$,

5) –CH_2CF_3,

6) –OCH_2CF_3,

7) –CF_2CH_3,

8) CN,

9) oxo,

10) halogen,

11) –S(O)$_2$C$_{1-6}$alkyl,

12) -C$_{1-6}$alkyl,

13) -C$_{2-6}$alkenyl,

14) -C$_{2-6}$alkynyl,

15) -O-C$_{1-6}$alkyl,

16) -C$_{3-6}$cycloalkyl,

17) -O-C$_{3-6}$cycloalkyl,

18) -C$_{2-6}$cycloheteroalkyl,

19) aryl,

20) heteroaryl,

21) –C$_{1-6}$alkyl-aryl,

22) –C$_{1-6}$alkyl-heteroaryl,

23) –C$_{1-6}$alkyl-C$_{3-6}$cycloalkyl,

24) –C$_{1-6}$alkyl-C$_{2-6}$cycloheteroalkyl,

25) -C$_{2-6}$alkenyl-C$_{3-6}$cycloalkyl,

26) -C$_{2-6}$alkenyl-C$_{2-6}$cycloheteroalkyl,

27) –C$_{2-6}$alkenyl-aryl,

28) -C$_{2-6}$alkenyl-heteroaryl,

29) -C$_{2-6}$alkynyl-C$_{3-6}$cycloalkyl,

30) -C$_{2-6}$alkynyl-C$_{2-6}$cycloheteroalkyl,

31) -C$_{2-6}$alkynyl-aryl,

32) -C$_{2-6}$alkynyl–heteroaryl,

33) -OH,

34) -(CH$_2$)$_q$-OC$_{1-6}$alkyl,

35) -(CH$_2$)$_q$ -OC$_{2-6}$alkenyl,

36) -(CH$_2$)$_q$ -OC$_{2-6}$alkynyl,

37) –(CH$_2$)$_q$ -OC$_{3-6}$cycloalkyl,

38) –(CH$_2$)$_q$ -OC$_{2-6}$heterocycloalkyl,

39) –(CH$_2$)$_q$ -O-aryl,

40) –(CH$_2$)$_q$ -O-heteroaryl,

41) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

42) -OC_{1-6}alkyl-C_{2-6}heterocycloalkyl,

43) -OC_{1-6}alkyl-aryl,

44) -OC_{1-6}alkyl-heteroaryl,

45) -$S(O)_mR^i$,

46) -C_{1-6}alkyl-$S(O)_mR^i$,

47) -$C(O)R^L$, and

48) –NR^kR^L,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

R^c is selected from:

1) -C_{1-6}alkyl,

2) OH,

3) halogen, and

4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^d is selected from:

1) -C_{1-6}alkyl,

2) OH,

3) halogen, and

4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^f is selected from:

1) -C_{1-6}alkyl,

2) OH,

3) halogen, and

4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^g is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^i is selected from:

1) hydrogen,
2) C_{1-6}alkyl,
3) C_{3-6}cycloalkyl,
4) aryl, and
5) heteroaryl;

R^k is selected from:

1) hydrogen, and
2) C_{1-6}alkyl;

R^L is selected from:

1) hydrogen,
2) C_{1-6}alkyl,
3) C_{3-6}cycloalkyl,
4) aryl, and
5) heteroaryl;

m is independently selected from 0 to 2;
p is independently selected from 0 to 3; and
q is independently selected from 0 to 3.

The compounds of structural formula I, and examples thereof, are inhibitors of $Na_v1.8$ sodium ion channel activity (or $Na_v1.8$ inhibitors) and may be useful in the treatment and prevention of diseases, disorders and conditions mediated by $Na_v1.8$ sodium ion channel activity, such as nociception, osteoarthritis, peripheral neuropathy, inherited erythromelalgia, multiple sclerosis, asthma, itch, atopy, allergic or contact dermatitis, renal failure, cholestasis, pruritus,

acute itch, chronic itch, migraine, neurodegeneration following ischemia, epilepsy, pain, inflammatory pain, spontaneous pain, acute pain, acute pain due to fractures, musculoskeletal damage, pancreatitis and renal colic, peri-operative pain, post-operative pain, neuropathic pain, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, chronic lower back pain, phantom limb pain, sciatica, pain caused by 2° or 3° burn injury, optic neuritis, pain resulting from cancer and chemotherapy, chronic pelvic pain, pain syndromes, and complex regional pain syndromes. In one example of the present disclosure, the condition, disease or disorder is a pain disorder, an acute pain disorder or chronic pain disorder. In another example of the present disclosure, the condition, disease or disorder is an acute pain disorder.

The present disclosure also relates to pharmaceutical compositions comprising the compounds of the present disclosure and a pharmaceutically acceptable carrier. In another aspect, the present disclosure relates to a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure also relates to methods for the treatment, management, prevention, alleviation, amelioration, suppression or control of disorders, diseases, and conditions that may be responsive to inhibition of $Na_v1.8$ sodium ion channel activity in a subject in need thereof by administering the compounds and pharmaceutical compositions of the present disclosure.

The present disclosure also relates to the use of compounds of the present disclosure for manufacture of a medicament useful in treating diseases, disorders and conditions that may be responsive to the inhibition of $Na_v1.8$ sodium ion channel activity.

In another aspect, the present disclosure relates to use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for the treatment of a disorder, condition, or disease that is responsive to the inhibition of $Na_v1.8$ channel activity in a mammal in need thereof.


In another aspect, the present disclosure relates to use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

In another aspect, the present disclosure relates to a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in therapy.

The present disclosure is also concerned with treatment or prevention of these diseases, disorders and conditions by administering the compounds of the present disclosure in combination with a therapeutically effective amount of another agent that may be useful to treat the disease, disorder and condition. The disclosure is further concerned with processes for preparing the compounds of this disclosure.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is concerned with novel compounds of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

one of A and B is selected from:

1) aryl, and

2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^a, and


the other of A and B is selected from:

1) aryl,

2) heteroaryl,

WHAT IS CLAIMED IS:

1. A compound of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

A is selected from the group consisting of:

1) phenyl, and
2) pyridine,

wherein each phenyl and pyridine is unsubstituted or substituted with one to five substituents selected from R^a,

B is independently selected from the group consisting of:

1) phenyl,
2) pyridine,
3) thiazole,
4) pyrimidine,
5) pyrazine,
6) pyridazine,
7) imidazole,
8) pyrazole,
9) oxazole,
10) benzofuran,
11) benzo[d]oxazole,
12) benzo[d]thiazole,

13) indazole,
14) thiazolo[5,4-b]pyridine,
15) pyrazolo[1,5-a]pyridine,
16) -$(CH_2)_2$-phenyl,
17) -CH_2-O-phenyl,
18) -CH_2-O-pyridine,
19) cyclobutane,
20) cyclohexane,
21) bicyclo[1.1.1]pentane,
22) spiro[3.3]heptane,
23) azetidine,
24) piperidine,
25) tetrahydropyran,
26) tetrahydrofuran,
27) azabicyclo[3.1.0]hexane,
28) -CH_2-cyclohexane,
29) -CH_2-tetrahydropyran,
30) -CH_2-O-cyclohexane, and
31) bicyclo[4.2.0]octatriene,

wherein B is unsubstituted or substituted with one to five substituents selected from R^b;

R^1 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^4 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^5 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

R^6 is hydrogen;

R^7 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

each R^a is independently selected from the group consisting of:

1) -CF_3,
2) -OCF_3,
3) -CHF_2,
4) -$OCHF_2$,
5) –CH_2CF_3,
6) –OCH_2CF_3,

7) $-CF_2CH_3$,

8) CN,

9) oxo,

10) halogen,

11) $-S(O)_2C_{1\text{-}6}$alkyl,

12) -$C_{1\text{-}6}$alkyl,

13) -$C_{2\text{-}6}$alkenyl,

14) -$C_{2\text{-}6}$alkynyl,

15) -$C_{3\text{-}6}$cycloalkyl,

16) -$C_{2\text{-}6}$cycloheteroalkyl,

17) aryl,

18) heteroaryl,

19) $-C_{1\text{-}6}$alkyl-aryl,

20) $-C_{1\text{-}6}$alkyl-heteroaryl,

21) $-C_{1\text{-}6}$alkyl-$C_{3\text{-}6}$cycloalkyl,

22) $-C_{1\text{-}6}$alkyl-$C_{2\text{-}6}$cycloheteroalkyl,

23) -$C_{2\text{-}6}$alkenyl-$C_{3\text{-}6}$cycloalkyl,

24) -$C_{2\text{-}6}$alkenyl-$C_{2\text{-}6}$cycloheteroalkyl,

25) $-C_{2\text{-}6}$alkenyl-aryl,

26) -$C_{2\text{-}6}$alkenyl-heteroaryl,

27) -$C_{2\text{-}6}$alkynyl-$C_{3\text{-}6}$cycloalkyl,

28) -$C_{2\text{-}6}$alkynyl-$C_{2\text{-}6}$cycloheteroalkyl,

29) -$C_{2\text{-}6}$alkynyl-aryl,

30) -$C_{2\text{-}6}$alkynyl-heteroaryl,

31) -OH,

32) -$(CH_2)_p$-O-$C_{1\text{-}6}$alkyl,

33) -$(CH_2)_p$ -O-$C_{2\text{-}6}$alkenyl,

34) -$(CH_2)_p$ -O-$C_{2\text{-}6}$alkynyl,

35) $-(CH_2)_p$ -O-$C_{3\text{-}6}$cycloalkyl,

36) $-(CH_2)_p$ -O-$C_{2\text{-}6}$heterocycloalkyl,

37) $-(CH_2)_p$ -O-aryl,

38) –$(CH_2)_p$ -O-heteroaryl,

39) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

40) -OC_{1-6}alkyl-C_{2-6}heterocycloalkyl,

41) -OC_{1-6}alkyl-aryl,

42) -OC_{1-6}alkyl-heteroaryl,

43) -$S(O)_mR^i$,

44) -C_{1-6}alkyl-$S(O)_mR^i$,

45) -$N(R^k)_2$, and

46) –NR^kR^L,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) -CHF_2,

4) -$OCHF_2$,

5) –CH_2CF_3,

6) –OCH_2CF_3,

7) –CF_2CH_3,

8) CN,

9) oxo,

10) halogen,

11) –$S(O)_2C_{1-6}$alkyl,

12) -C_{1-6}alkyl,

13) -C_{2-6}alkenyl,

14) -C_{2-6}alkynyl,

15) -O-C_{1-6}alkyl,

16) -C_{3-6}cycloalkyl,

17) -O-C_{3-6}cycloalkyl,

18) -C_{2-6}cycloheteroalkyl,

19) aryl,

20) heteroaryl,

21) –C_{1-6}alkyl-aryl,

22) –C_{1-6}alkyl-heteroaryl,

23) –C_{1-6}alkyl-C_{3-6}cycloalkyl,

24) –C_{1-6}alkyl-C_{2-6}cycloheteroalkyl,

25) -C_{2-6}alkenyl-C_{3-6}cycloalkyl,

26) -C_{2-6}alkenyl-C_{2-6}cycloheteroalkyl,

27) –C_{2-6}alkenyl-aryl,

28) -C_{2-6}alkenyl-heteroaryl,

29) -C_{2-6}alkynyl-C_{3-6}cycloalkyl,

30) -C_{2-6}alkynyl-C_{2-6}cycloheteroalkyl,

31) -C_{2-6}alkynyl-aryl,

32) -C_{2-6}alkynyl–heteroaryl,

33) -OH,

34) -$(CH_2)_q$-OC_{1-6}alkyl,

35) -$(CH_2)_q$ -OC_{2-6}alkenyl,

36) -$(CH_2)_q$ -OC_{2-6}alkynyl,

37) –$(CH_2)_q$ -OC_{3-6}cycloalkyl,

38) –$(CH_2)_q$ -OC_{2-6}heterocycloalkyl,

39) –$(CH_2)_q$ -O-aryl,

40) –$(CH_2)_q$ -O-heteroaryl,

41) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

42) -OC_{1-6}alkyl-C_{2-6}heterocycloalkyl,

43) -OC_{1-6}alkyl-aryl,

44) -OC_{1-6}alkyl-heteroaryl,

45) -$S(O)_mR^i$,

46) -C_{1-6}alkyl-$S(O)_mR^i$,

47) -$C(O)R^L$, and

48) –NR^kR^L,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

R^c is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^d is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^f is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^g is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^i is selected from:

1) hydrogen,
2) C_{1-6}alkyl,
3) C_{3-6}cycloalkyl,
4) aryl, and
5) heteroaryl;

R^k is selected from:
1) hydrogen, and
2) C_{1-6}alkyl;

R^L is selected from:
1) hydrogen,
2) C_{1-6}alkyl,
3) C_{3-6}cycloalkyl,
4) aryl, and
5) heteroaryl;

m is independently selected from 0 to 2;
p is independently selected from 0 to 3; and
q is independently selected from 0 to 3.

2. The compound according to Claim 1 wherein A is phenyl, wherein phenyl is unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 wherein B is independently selected from the group consisting of:
1) phenyl,
2) pyridine,
3) thiazole, and
4) cyclobutane,
wherein B is unsubstituted or substituted with one to five substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 wherein R^1, R^2, R^3, R^4, R^5, R^6 and R^7 are each hydrogen; or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1 wherein

A is selected from the group consisting of:

1) phenyl, and
2) pyridine,

wherein each phenyl and pyridine is unsubstituted or substituted with one to five substituents selected from R^a;

B is independently selected from the group consisting of:

1) phenyl,
2) pyridine,
3) thiazole,
4) pyrimidine,
5) pyrazine,
6) pyridazine,
7) imidazole,
8) pyrazole,
9) oxazole,
10) benzofuran,
11) benzo[d]oxazole,
12) benzo[d]thiazole,
13) indazole,
14) thiazolo[5,4-b]pyridine,
15) pyrazolo[1,5-a]pyridine,
16) $-(CH_2)_2$-phenyl,
17) $-CH_2$-O-phenyl,
18) $-CH_2$-O-pyridine,
19) cyclobutane,
20) cyclohexane,
21) bicyclo[1.1.1]pentane,

22) spiro[3.3]heptane,

23) azetidine,

24) piperidine,

25) tetrahydropyran,

26) tetrahydrofuran,

27) azabicyclo[3.1.0]hexane,

28) -CH_2-cyclohexane,

29) -CH_2-tetrahydropyran,

30) -CH_2-O-cyclohexane, and

31) bicyclo[4.2.0]octatriene,

wherein B is unsubstituted or substituted with one to five substituents selected from R^b;

R^1 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^4 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from Rg;

R^6 is hydrogen;

R^7 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

each R^a is independently selected from the group consisting of:

1) -CF_3,
2) -OCF_3,
3) -CHF_2,
4) -OCH_2CF_3,
5) CN,
6) halogen, and
7) -C_{2-6}alkynyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group consisting of:

1) -CF_3,
2) -OCF_3,
3) -CHF_2,
4) -$OCHF_2$,
5) –CH_2CF_3,
6) –$CH(CF_3)CH_3$,
7) –OCH_2CF_3,
8) CN,
9) halogen,

10) –S(O)$_2$C$_{1\text{-}6}$alkyl,

11) -C$_{1\text{-}6}$alkyl, and

12) -C$_{3\text{-}6}$cycloalkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C$_{1\text{-}6}$alkyl, and O-C$_{1\text{-}6}$alkyl;

or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 1 wherein

A is phenyl, wherein phenyl is unsubstituted or substituted with one to five substituents selected from R^a;

B is independently selected from the group consisting of:

1) phenyl,

2) pyridine,

3) thiazole, and

4) cyclobutane,

wherein B is unsubstituted or substituted with one to five substituents selected from R^b;

R^1, R^2, R^3, R^4, R^5, R^6 and R^7 are hydrogen;

each R^a is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3, and

3) halogen;

each R^b is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) –OCH_2CF_3, and

4) halogen,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -$C_{1\text{-}6}$alkyl, and O-$C_{1\text{-}6}$alkyl;
or a pharmaceutically acceptable salt thereof.

7. The compound according to Claim 1 selected from:

1) (S)-N-((R)-2-(3-chloro-4-fluorophenoxy)-1-(3-chloro-4-fluorophenyl)ethyl)-2-oxoimidazolidine-4-carboxamide;
2) (S)-N-((S)-2-(3-chloro-4-fluorophenoxy)-1-(3-chloro-4-fluorophenyl)ethyl)-2-oxoimidazolidine-4-carboxamide;
3) (R)-N-(bis(4-chlorophenyl)methyl)-3-methyl-2-oxoimidazolidine-4-carboxamide and (S)-N-(bis(4-chlorophenyl)methyl)-3-methyl-2-oxoimidazolidine-4-carboxamide;
4) (S)-N-((R)-(5-chloro-6-(difluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;
5) (S)-N-((S)-(5-chloro-6-(difluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;
6) (S)-N-((R)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;
7) (S)-N-((S)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;
8) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(1-(1-(trifluoromethyl)cyclopropyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;
9) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(1-(1-(trifluoromethyl)cyclopropyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;
10) (S)-N-((5-chloro-4-(trifluoromethyl)pyrimidin-2-yl)(4-chlorophenyl)methyl)-2-oxoimidazolidine-4-carboxamide;
11) (S)-N-((R)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;
12) (S)-N-((S)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;
13) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

14) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

15) (S)-N-((R)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

16) (S)-N-((S)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

17) (R)-N-[bis(4-chlorophenyl)methyl]-1-methyl-2-oxoimidazolidine-4-carboxamide;

18) (S)-N-[bis(4-chlorophenyl)methyl]-1-methyl-2-oxoimidazolidine-4-carboxamide;

19) (4S)-N-{((R)-3-chloro-4-fluorophenyl)[5-fluoro-6-(2,2,2-trifluoro-ethoxy)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

20) (4S)-N-{((S)-3-chloro-4-fluorophenyl)[5-fluoro-6-(2,2,2-trifluoro-ethoxy)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

21) (4S)-N-[((R)-3-chloro-4-fluorophenyl)(6-cyanopyridin-2-yl)methyl]-2-oxoimidazolidine-4-carboxamide;

22) (4S)-N-[((S)-3-chloro-4-fluorophenyl)(6-cyanopyridin-2-yl)methyl]-2-oxoimidazolidine-4-carboxamide;

23) (4S)-N-[((R)-5-chloro-6-cyclopropylpyridin-3-yl)(3-chloro-2,4-difluoro-phenyl)methyl]-2-oxoimidazolidine-4-carboxamide;

24) (4S)-N-[((S)-5-chloro-6-cyclo-propylpyridin-3-yl)(3-chloro-2,4-difluoro-phenyl)methyl]-2-oxoimidazolidine-4-carboxamide;

25) (4S)-N-{[(R)-5-chloro-6-(trifluoromethyl)pyridin-3-yl][5-fluoro-6-(trifluoro-methyl)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

26) (4S)-N-{[(S)-5-chloro-6-(trifluoromethyl)pyridin-3-yl][5-fluoro-6-(trifluoro-methyl)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

27) (S)-N-((R)-(3-chloro-4-fluorophenyl)(cis-2,6-dimethyl-1-(2,2,2-trifluoroethyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

28) (S)-N-((S)-(3-chloro-4-fluorophenyl)(cis-2,6-dimethyl-1-(2,2,2-trifluoroethyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

29) (S)-N-((R)-(3-chloro-4-fluorophenyl)(2-(1-(trifluoromethyl)cyclopropyl)thiazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

30) (S)-N-((S)-(3-chloro-4-fluorophenyl)(2-(1-(trifluoromethyl)cyclopropyl)thiazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

31) (S)-N-((R)-(4-chlorophenyl)(4-fluoro-3-(trifluoro-methyl)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

32) (S)-N-((S)-(4-chlorophenyl)(4-fluoro-3-(trifluoro-methyl)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

33) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)(4-cyano-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

34) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)(4-cyano-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

35) (S)-2-oxo-N-((R)-(6-(trifluoromethyl)pyridin-3-yl)(2-(trifluoromethyl)thiazol-4-yl)methyl)imidazolidine-4-carboxamide;

36) (S)-2-oxo-N-((S)-(6-(trifluoromethyl)pyridin-3-yl)(2-(trifluoromethyl)thiazol-4-yl)methyl)imidazolidine-4-carboxamide;

37) (R)-N-(bis(4-chlorophenyl)methyl)-4-methyl-2,5-dioxoimidazolidine-4-carboxamide;

38) (S)-N-(bis(4-chlorophenyl)methyl)-4-methyl-2,5-dioxoimidazolidine-4-carboxamide;

39) (R)-N-(bis(4-chlorophenyl)methyl)-3-(2-hydroxyethyl)-2-oxoimidazolidine-4-carboxamide;

40) (S)-N-(bis(4-chlorophenyl)methyl)-3-(2-hydroxyethyl)-2-oxoimidazolidine-4-carboxamide;

41) (S)-N-((R)-(4-chlorophenyl)(2-(trifluoromethyl)-1H-imidazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

42) (S)-N-((S)-(4-chlorophenyl)(2-(trifluoromethyl)-1H-imidazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

43) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((cis)-4-(trifluoromethyl)cyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

44) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((trans)-4-(trifluoromethyl)cyclohexyl)-ethyl)-2-oxoimidazolidine-4-carboxamide;

45) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((trans)-4-(trifluoromethyl)cyclohexyl)-ethyl)-2-oxoimidazolidine-4-carboxamide;

46) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((cis)-4-(trifluoromethyl)cyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

47) (4S)-N-{(R)- (3-chloro-2,4-difluorophenyl)[6-(trifluoromethoxy)pyridin-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

48) (4S)-N-{(S)- (3-chloro-2,4-difluorophenyl)[6-(trifluoromethoxy)pyridin-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

49) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-(4,4-difluorocyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

50) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-(4,4-difluorocyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

51) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((R)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

52) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((S)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

53) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((R)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

54) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((S)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

55) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

56) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

57) ((4S)-N-{(R)-(3-chloro-4-fluorophenyl)[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

58) (4S)-N-{(S)-(3-chloro-4-fluorophenyl)[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

59) (4S)-N-{1-((R)-3-chloro-4-fluorophenyl)-2-[(4,4-difluoro-cyclohexyl)oxy]ethyl}-2-oxoimidazolidine-4-carboxamide;

60) (4S)-N-{1-((S)-3-chloro-4-fluorophenyl)-2-[(4,4-difluoro-cyclohexyl)oxy]ethyl}-2-oxoimidazolidine-4-carboxamide;

61) (4S)-N-[(R)-(3-chloro-2,4-di-fluorophenyl)(3,3-dimethylcyclobutyl)methyl]-2-oxoimidazolidine-4-carboxamide;

62) (4S)-N-[(S)-(3-chloro-2,4-di-fluorophenyl)(3,3-dimethylcyclobutyl)methyl]-2-oxoimidazolidine-4-carboxamide;

63) (S)-N-((R)-(3-chloro-4-fluorophenyl)(1-methyl-3-(tri-fluoromethyl)-1H-pyrazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

64) (S)-N-((S)-(3-chloro-4-fluorophenyl)(1-methyl-3-(tri-fluoromethyl)-1H-pyrazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

65) (S)-N-((R)-(3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-2-oxoimidazolidine-4-carboxamide;

66) (S)-N-((S)-(3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-2-oxoimidazolidine-4-carboxamide;

67) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

68) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

69) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

70) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

71) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(2,2,2-trifluoroethoxy)thiazol-5-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

72) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(2,2,2-trifluoroethoxy)thiazol-5-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

73) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

74) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

75) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6,6-difluorospiro[3.3]heptan-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

76) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6,6-difluorospiro[3.3]heptan-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

77) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

78) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

79) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

80) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

81) (S)-N-((R)-3-chloro-4-(trifluoromethoxy)phenyl)(5-(trifluoromethoxy)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

82) (S)-N-((S)-3-chloro-4-(trifluoromethoxy)phenyl)(5-(trifluoromethoxy)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

83) (S)-N-((R)-(5-chloro-6-cyclopropylpyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

84) (S)-N-((S)-(5-chloro-6-cyclopropylpyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

85) (S)-N-((R)-(3-chloro-4-(trifluoromethoxy)phenyl)(1-(trifluoromethyl)-1H-pyrazol-4-yl)-l3-methyl)-2-oxoimidazolidine-4-carboxamide;

86) (S)-N-((S)-(3-chloro-4-(trifluoromethoxy)phenyl)(1-(trifluoromethyl)-1H-pyrazol-4-yl)-l3-methyl)-2-oxoimidazolidine-4-carboxamide;

87) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethoxy)-5-fluoropyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

88) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethoxy)-5-fluoropyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

89) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

90) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

91) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

92) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

93) (S)-N-((R)-(5-fluoro-6-(trifluoro-methyl)pyridin-2-yl)(6-(trifluoromethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

94) (S)-N-((S)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(6-(trifluoromethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

95) (S)-N-((R)-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)(5-fluoro-6-(trifluoro-methyl)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

96) (S)-N-((S)-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)(5-fluoro-6-(trifluoro-methyl)-pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

97) (S)-N-((R)-(3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide

98) (S)-N-((S)-(3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

99) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(trifluoromethyl)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

100) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(trifluoromethyl)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

101) (S)-N-((R)-3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)pyrimidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

102) (S)-N-((S)-3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)pyrimidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

103) (4S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

104) (4S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

105) (4S)-N-((R)-(3-chloro-2,4-difluorophenyl)(5-(2,2,2-trifluoroethoxy)pyrazin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

106) (4S)-N-((S)-(3-chloro-2,4-difluorophenyl)(5-(2,2,2-trifluoroethoxy)pyrazin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

107) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-3-(4-chlorophenyl)propyl)-2-oxo-imidazolidine-4-carboxamide;

108) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-3-(4-chlorophenyl)propyl)-2-oxo-imidazolidine-4-carboxamide;

109) (4S)-N-(1-(3-chloro-4-fluorophenyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)ethyl)-2-oxoimidazolidine-4-carboxamide;

110) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-cyclohexylethyl)-2-oxoimidazolidine-4-carboxamide;

111) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-cyclohexylethyl)-2-oxoimidazolidine-4-carboxamide;

112) (4S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

113) (4S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

114) (S)-N-((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)-pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

115) (S)-N-((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)-pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

116) (S)-N-((R)-(4-chloro-3-cyanophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

117) (S)-N-((S)-(4-chloro-3-cyanophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

118) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((R)-1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

119) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((S)-1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

120) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((S)-1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

121) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

122) (S)-N-((R)-(4-chlorophenyl)(5-fluoro-4-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

123) (S)-N-((S)-(4-chlorophenyl)(5-fluoro-4-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

124) (S)-N-((R)-(4-chloro-3-(trifluoromethyl)-phenyl)(4-cyanophenyl)-methyl)-2-oxo-imidazolidine-4-carboxamide;

125) (S)-N-((S)-(4-chloro-3-(trifluoromethyl)-phenyl)(4-cyanophenyl)-methyl)-2-oxo-imidazolidine-4-carboxamide;

126) (S)-N-(bis(3-chloro-4-fluorophenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

127) (S)-N-((R)-(3-chloro-4-fluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

128) (S)-N-((S)-(3-chloro-4-fluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

129) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)-5-fluoropyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

130) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)-5-fluoropyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

131) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

132) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

133) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((S)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

134) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((R)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

135) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((S)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

136) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((R)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

137) (S)-N-((R)-(3-chloro-4-fluorophenyl)(2-methylbenzo[d]thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

138) (S)-N-((S)-(3-chloro-4-fluorophenyl)(2-methylbenzo[d]thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

139) (S)-N-((R)-(3-chloro-4-fluorophenyl)(trans-2-(trifluoromethyl)cyclobutyl)methyl)-2-oxoimidazolidine-4-carboxamide;

140) (S)-N-((S)-(3-chloro-4-fluorophenyl)(trans-2-(trifluoromethyl)cyclobutyl)methyl)-2-oxoimidazolidine-4-carboxamide;

141) (4S)-N-((3-chloro-4-fluorophenyl)(3,3-dimethyl-2-(trifluoromethyl)cyclobutyl)methyl)-2-oxoimidazolidine-4-carboxamide;

142) (4S)-N-((3-chloro-4-fluorophenyl)(4-fluorobicyclo[4.2.0]octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

143) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

144) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

145) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

146) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

147) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

148) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

149) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

150) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

151) (4S)-N-((3-chloro-4-fluorophenyl)(4-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

152) (4S)-N-((3-chloro-4-fluorophenyl)(thiazolo[5,4-b]pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

153) (S)-N-((R)-(3-chloro-4-fluorophenyl)(5-chlorobenzofuran-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

154) (S)-N-((S)-(3-chloro-4-fluorophenyl)(5-chlorobenzofuran-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

155) (S)-N-((R)-(4-chlorophenyl)(6-(difluoromethoxy)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

156) (S)-N-((S)-(4-chlorophenyl)(6-(difluoromethoxy)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

157) (S)-N-((R)-(4-chlorophenyl)(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

158) (S)-N-((S)-(4-chlorophenyl)(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

159) (4S)-N-((4-chlorophenyl)(4-methyl-2-(trifluoro-methyl)thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

160) (4S)-N-((1(R))-(3-chloro-4-fluorophenyl)(3-(2,2,2-trifluoroethyl)-3-azabicyclo-[3.1.0]hexan-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

161) (4S)-N-((1(S))-(3-chloro-4-fluorophenyl)(3-(2,2,2-trifluoroethyl)-3-azabicyclo-[3.1.0]-hexan-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

162) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((cis)-1-methyl-2-(trifluoro-methyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

163) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((trans)-1-methyl-2-(trifluoro-methyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

164) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((cis)-1-methyl-2-(trifluoro-methyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

165) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-1-methyl-2-(trifluoro-methyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

166) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((cis)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

167) S)-N-((R)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

168) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((cis)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

169) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

170) (S)-N-((R)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

171) (S)-N-((S)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

172) (4S)-N-(benzo[d]thiazol-6-yl(4-chlorophenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

173) (S)-N-((R)-(4-chlorophenyl)(1H-indazol-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

174) (S)-N-((S)-(4-chlorophenyl)(1H-indazol-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

175) (S)-N-((R)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

176) (S)-N-((S)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

177) (S)-N-((R)-(4-chlorophenyl)(2-methylbenzo[d]oxazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

178) (S)-N-((S)-(4-chlorophenyl)(2-methylbenzo[d]oxazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

179) (S)-N-((R)-(4-chlorophenyl)(2-methylbenzo[d]thiazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

180) (S)-N-((S)-(4-chlorophenyl)(2-methylbenzo[d]thiazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

181) (S)-N-((R)-(3-chloro-4-fluorophenyl)(4-(methylsulfonyl)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

182) (S)-N-((S)-(3-chloro-4-fluorophenyl)(4-(methylsulfonyl)phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

183) (4S)-N-[(3-chloro-4-fluorophenyl)(5-cyanopyridin-2-yl)methyl]-2-oxoimidazolidine-4-carboxamide;

184) (S)-N-((R)-benzo[d]thiazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

185) (S)-N-((S)-benzo[d]thiazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

186) (S)-N-((R)-benzo[d]oxazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

187) (S)-N-((S)-benzo[d]oxazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

188) (S)-N-((R)-(8,8-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)(4-(trifluoromethoxy)-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

189) (S)-N-((S)-(8,8-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)(4-(trifluoromethoxy)-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

190) (S)-N-((R)-(4-chlorophenyl)(7,7-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

191) (S)-N-((S)-(4-chlorophenyl)(7,7-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

192) (4S)-N-((R)(4-chlorophenyl)((R)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

193) (4S)-N-((R)(4-chlorophenyl)((S)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

194) (4S)-N-((S)(4-chlorophenyl)((S)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide; and

195) (4S)-N-((S)(4-chlorophenyl)((R)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

or a pharmaceutically acceptable salt thereof.

8. The compound according to Claim 7 which is: (S)-N-((R)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)-phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

9. The compound according to Claim 7 which is: (S)-N-((S)-(5-fluoro-6-(trifluoromethyl) yridine-2-yl)(4-(trifluoromethoxy)-phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

10. The compound according to Claim 7 which is: (S)-N-((R)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 7 which is: (S)-N-((S)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

12. The compound according to Claim 7 which is: (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 7 which is: (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

14. The compound according to Claim 7 which is: (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

15. The compound according to Claim 7 which is: (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound of any one of Claims 1-15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. Use of a compound according to any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for the treatment of a disorder, condition, or disease that is responsive to the inhibition of $Na_v1.8$ channel activity in a mammal in need thereof.

18. Use of a compound of any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

19. The use of Claim 18 wherein the disorder is a pain disorder.

20. The use of Claim 19 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.

21. A compound according to any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, for use in therapy.